Company & Sponsor Intelligence

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed3

Countries1

Therapeutic footprint

alzheimers

Indexed studies

NCT00112073AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT01284387Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT00021723Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
alzheimers · United StatesPHASE3

NCT00937352A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →